Cardinal reaffirms fiscal guidance and long-term targets amidst nonrenewal of OptumRx customer contracts
Cardinal Health announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35.